stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Return on equity
Haemonetics Corporation's return on equity over the twelve months to 30 September 2026 was 11.9%, down 0.1 percentage points from fiscal 2026 (12.0%). Over the past ten years it has ranged from −7.18% (fiscal 2016) to 18.8% (fiscal 2025); the current reading is higher than 58% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | 12.0% | (6.80) |
| FY2025 | 18.8% | 5.61 |
| FY2024 | 13.2% | (1.50) |
| FY2023 | 14.7% | 8.86 |
| FY2022 | 5.86% | (6.19) |
| FY2021 | 12.1% | (0.15) |
| FY2020 | 12.2% | 4.45 |
| FY2019 | 7.75% | 1.64 |
| FY2018 | 6.11% | 9.71 |
| FY2017 | −3.60% | 3.58 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LIVN LivaNova PLC compare | 15.5% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 14.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 14.3% |
| HAE Haemonetics Corporation | 11.9% |
| ITGR Integer Holdings Corporation compare | 5.97% |
| BRKR Bruker Corporation compare | −7.04% |
| TXG 10x Genomics compare | −9.40% |
| AXGN AxoGen, Inc. compare | −10.4% |
| IRTC iRhythm Holdings, Inc. compare | −25.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement